Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
Louis Boiron, Elmar A. Joura, Nathalie Largeron, et al.
BMC Infectious Diseases (2016) Vol. 16, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing
Andreas C. Chrysostomou, Dora C. Stylianou, Anastasia Constantinidou, et al.
Viruses (2018) Vol. 10, Iss. 12, pp. 729-729
Open Access | Times Cited: 217
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
Carlo Signorelli, Anna Odone, Veronica Ciorba, et al.
Epidemiology and Infection (2017) Vol. 145, Iss. 10, pp. 1962-1982
Open Access | Times Cited: 67
Cervical cancer in Zimbabwe: a situation analysis
Oppah Kuguyo, Alice Matimba, Nomsa Tsikai, et al.
Pan African Medical Journal (2017) Vol. 27
Open Access | Times Cited: 63
Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination
Siok Shen Ng, Raymond Hutubessy, Nathorn Chaiyakunapruk
Vaccine (2018) Vol. 36, Iss. 19, pp. 2529-2544
Closed Access | Times Cited: 61
Framework for developing cost-effectiveness analysis threshold: the case of Egypt
Ahmad Nader Fasseeh, Nada Korra, Baher Elezbawy, et al.
Journal of the Egyptian Public Health Association (2024) Vol. 99, Iss. 1
Open Access | Times Cited: 5
Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study
Vojtěch Kamenský, Lukáš Dostálek, Martin Rožánek, et al.
BMC Public Health (2025) Vol. 25, Iss. 1
Open Access
Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study
Meng Gao, Shangying Hu, Xuelian Zhao, et al.
The Lancet Regional Health - Western Pacific (2025) Vol. 56, pp. 101499-101499
Open Access
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies
Daniel D de Bondt, Emi Naslazi, Erik E.L. Jansen, et al.
Gynecologic Oncology (2025) Vol. 195, pp. 134-143
Open Access
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
Francesco Saverio Mennini, Paolo Bonanni, F. Bianic, et al.
Cost Effectiveness and Resource Allocation (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 43
Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
Suzanne M. Garland, Punnee Pitisuttithum, Hys Ngan, et al.
The Journal of Infectious Diseases (2018) Vol. 218, Iss. 1, pp. 95-108
Open Access | Times Cited: 42
Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study
Cody Palmer, Keisuke Tobe, Machiko Abe, et al.
BMC Infectious Diseases (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 31
An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
Nathalie Largeron, Karl Ulrich Petry, Jorge Jacob, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2016) Vol. 17, Iss. 1, pp. 85-98
Closed Access | Times Cited: 37
Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
Rashidul Alam Mahumud, Khorshed Alam, Syed Afroz Keramat, et al.
PLoS ONE (2020) Vol. 15, Iss. 6, pp. e0233499-e0233499
Open Access | Times Cited: 25
Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands
Venetia Qendri, Johannes A. Bogaards, Johannes Berkhof
The Journal of Infectious Diseases (2017) Vol. 216, Iss. 2, pp. 210-219
Open Access | Times Cited: 28
HPV prevalence in vulvar cancer in Austria
Sophie Pils, Lisa Gensthaler, Laia Alemany, et al.
Wiener klinische Wochenschrift (2017) Vol. 129, Iss. 21-22, pp. 805-809
Open Access | Times Cited: 27
Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine
Zhigang Zhang, Jun Zhang, Ningshao Xia, et al.
Human Vaccines & Immunotherapeutics (2017) Vol. 13, Iss. 10, pp. 2280-2291
Open Access | Times Cited: 26
Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
Jesús de la Fuente, Juan José Hernández Aguado, María San Martín, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 7-8, pp. 1949-1961
Open Access | Times Cited: 24
Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France
Laureen Majed, Xavier Bresse, Nadia El Mouaddin, et al.
Vaccine (2020) Vol. 39, Iss. 2, pp. 438-446
Closed Access | Times Cited: 22
Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness
Nyi Nyi Soe, Jason J. Ong, Xiaomeng Ma, et al.
Human Vaccines & Immunotherapeutics (2018) Vol. 14, Iss. 12, pp. 3010-3018
Open Access | Times Cited: 22
VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation
Yu Xie, Xiaodong Tan, Haiyan Shao, et al.
BMC Public Health (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 20
Ein Jahrzehnt der HPV-Impfung in Deutschland
P. Schneede
Der Urologe (2017) Vol. 56, Iss. 6, pp. 728-733
Closed Access | Times Cited: 19
Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis
Cheuk‐Wai Choi, Mark Jit, GM Leung, et al.
BMC Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 19
Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs
Raúl Murillo, Camila Ordóñez‐Reyes
International Journal of Gynecological Cancer (2019) Vol. 29, Iss. 8, pp. 1317-1326
Closed Access | Times Cited: 18
Clinical and economic impact of school‐based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis
S K Tay, T.Y. Hsu, Andrew Pavelyev, et al.
BJOG An International Journal of Obstetrics & Gynaecology (2017) Vol. 125, Iss. 4, pp. 478-486
Closed Access | Times Cited: 18
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
Tak Hong Cheung, Sally Shuk Yee Cheng, Danny Hsu, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top